CAR-T cell Therapy

What is CAR-T Cell Therapy?

CAR-T is named after a mythical creature called the chimera and refers to Chimeric Antigen Receptor T-Cell, which is characterized by genetic modification to obtain a personalized therapeutic method for carrying T cells that recognize tumor antigen-specific receptors. CAR-T is able to sense cells with specific proteins on its surface through its own receptors, lock infected cells and cancer cells in this way, and then kill them.

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has been validated in patients with acute lymphoblastic leukemia, and personalized treatment produces significant results.

How It Works?

The process for CAR T cell therapy can take a few weeks. As the figure 1 shows:

First, doctors collect immune T cells from an individual's peripheral blood using a procedure called leukapheresis.

Second, after the T-cells (a type of white cells) are collected from the patient, they are sent to the lab, and genetically engineered those cells to express cancer-specific chimeric antigen receptors (CARs) on their surface. The receptor functions as a type of "heat-seeking missile", enabling the modified cells to produce chemicals that kill cancer.

Third, a large number of CAR-T cells are cultured in vitro (called "ex vivo expansion"), and generally one patient needs several billions or even ten billion CAR-T cells.

Finally, once there are enough CAR-T cells, they will be re-infused into the patient in order to launch a precise attack against the cancer cells.

the processes of CAR-T cell therapy

Figure 1. The Processes of CAR-T Cell Therapy

The Typical Structure of CAR-T

A typical CAR on the cell’s surface is composed of an extracellular antigen binding region, a transmembrane region, and an intracellular signal transduction region. The domains that are used can affect how well the receptor recognizes or binds to the antigen on the tumor cell.

You can click the article named CAR-T Cell Therapy- An Useful Treatment To Cancer to read the full text about CAR-T cell therapy, including its structure, history of development and targets.

As you know, CAR T-cell therapy has advanced the furthest in clinical development as a star treatment to cancer. It is necessary to do a large amount of basic research. CUSABIO provides a series products of its targets and related cytokines involved in the processes of T cell differentiation.

Part of Hot Products

The SDS-PAGE of Recombinant Human CD19

Recombinant Human CD19
(CSB-CF004888HUc7)

The SDS-PAGE of Recombinant Human CD22

Recombinant Human CD22
(CSB-MP004900HU)

The SDS-PAGE of Recombinant Human PD-L1

Recombinant Human PD-L1
(CSB-MP878942HU1)

The SDS-PAGE of Recombinant Human CD133

Recombinant Human CD133
(CSB-YP018751HU)

The proteins of CAR-T cell therapy targets

Target Product Name Code Expression System
CD19 Recombinant Human B-lymphocyte antigen CD19(CD19),partialin CSB-CF004888HUc7 in vitro E.coli expression system
CD20 Recombinant Human B-lymphocyte antigen CD20(MS4A1) CSB-CF015007HU in vitro E.coli expression system
CD22 Recombinant Human B-cell receptor CD22(CD22),partial CSB-MP004900HU Mammalian cell
CD30 Recombinant Human Tumor necrosis factor receptor superfamily member 8(TNFRSF8) CSB-CF023983HU in vitro E.coli expression system
PD-L1 Recombinant Human Programmed cell death 1 ligand 1(CD274),partial CSB-MP878942HU1 Mammalian cell
CD133 Recombinant Human Prominin-1(PROM1),partial CSB-YP018751HU Yeast
CD123 Recombinant Human Interleukin-3 receptor subunit alpha(IL3RA) CSB-CF011658HU in vitro E.coli expression system
HER2 Recombinant Human Receptor tyrosine-protein kinase erbB-2(ERBB2),partial CSB-EP007763HU E.coli

The antibodies of CAR-T cell therapy targets

Target Product Name Code Species Reactivity Application
CD19 CD19 Monoclonal Antibody CSB-MA004888A0m Human ELISA, WB, IHC, IF, FC
CD20 MS4A1 Antibody CSB-PA015007DSR2HU Human ELISA, IHC
CD22 CD22 Antibody CSB-PA070294 Human WB, ELISA
CD30 TNFRSF8 Antibody CSB-PA912411 Human ELISA, IHC
PD-L1 CD274 Antibody CSB-PA004911GA01HU Human,Mouse,Rat ELISA, WB, IP, IHC, IF, FC
CD133 PROM1 Antibody CSB-PA018751GA01HU Human,Mouse,Rat ELISA,WB
CD123 IL3RA Antibody CSB-PA011658GA01HU Human ELISA,WB
HER2 ERBB2 Antibody CSB-PA007763KA01HU Human,Mouse,Rat ELISA,WB,IHC

The ELISA kits of CAR-T cell therapy targets

Target Product Name Code Sample Type Sensitivity
CD19 Human cluster of differentiation 19(CD19) ELISA Kit CSB-E14094h serum, plasma, tissue homogenates, cell lysates 0.039 ng/mL
CD20 Human B-lymphocyte antigen (CD20) ELISA Kit CSB-E14007h serum, plasma, tissue homogenates 0.78 ng/mL
CD22 Human cluster of differentiation 22(CD22) ELISA Kit CSB-E17496h Request Information Request Information
CD30 Human cluster of differentiation 30(CD30) ELISA Kit CSB-E17502h serum, plasma, cell culture supernates 3.9 pg/mL
PD-L1 Human Programmed Death Ligand-1(PD-L1/CD274) ELISA Kit CSB-E13644h serum, plasma, tissue homogenates, cell lysates 3.9 pg/mL
CD133 Human Prominin-1(PROM1) ELISA kit CSB-EL018751HU serum, plasma, tissue homogenates, cell lysates 0.078 ng/mL
CD123 Human Interleukin-3 receptor subunit alpha(IL3RA) ELISA kit CSB-EL011658HU serum, plasma, tissue homogenates, cell lysates 0.078 ng/mL
HER2 Human epidermal growth factor receptor 2 (sp185/HER2) ELISA Kit CSB-E11161h serum, plasma, tissue homogenates, cell lysates 0.04 ng/mL

Other related targets

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

Copyright © 2007-2018 www.cusabio.com CUSABIO TECHNOLOGY LLC All Rights Reserved.